I'm LongbridgeAI, I can summarize articles.BioLife Solutions has entered a definitive merger agreement to be acquired by Repligen. The deal involves an exchange of $11.25 in cash plus 0.1442 shares of Repligen common stock for each BioLife share. This two-step merger aims to make BioLife a wholly owned subsidiary, with closing expected in Q4 2026, subject to regulatory approvals and shareholder consent.
BioLife Solutions entered into a definitive Agreement and Plan of Merger with Repligen under which Repligen will acquire all outstanding BioLife shares for $11.25 in cash plus 0.1442 shares of Repligen common stock per BioLife share. The two-step merger will make BioLife a wholly owned subsidiary of Repligen, with no fractional Repligen shares issued (cash in lieu). Closing is expected in the fourth quarter of 2026, subject to BioLife stockholder approval, HSR clearance, SEC effectiveness of Repligen's S-4, Nasdaq listing of the new shares, and other customary conditions.
Agreement details:
- Agreement type: Agreement and Plan of Merger
- Counterparty: Repligen
- Signed / Effective: Jul 21 2026 / same
- Duration / Termination: Until closing
- Reason: Accelerate growth and expand cell therapy tools footprint
Original SEC Filing: BIOLIFE SOLUTIONS INC [ BLFS ] - 8-K - Jul. 22, 2026